Related Experiment Video

Updated: Apr 25, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.5K

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

Richard S Finkel1, Thomas O Crawford2, Eugenio Mercuri3,4

  • 1St. Jude Children's Research Hospital, Memphis, TN, USA. richard.finkel@stjude.org.

Nature Medicine
|April 23, 2026
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

8.7K
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

458

Related Experiment Videos

Last Updated: Apr 25, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.5K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

8.7K
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

458

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K

Articles linked to this work by shared authors, journal, and citation graph.

Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.

Nature reviews. Neurology·2026

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan.

Annals of clinical and translational neurology·2026

LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.

Nature medicine·2026

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Nature medicine·2026

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Nature medicine·2025

Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry.

Journal of neuromuscular diseases·2025

Histological aging signatures for monitoring tissue-specific aging and disease.

Nature medicine·2026

How to build an AI-driven digital organism.

Nature medicine·2026

First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

Nature medicine·2026

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

Nature medicine·2026

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

Nature medicine·2026

Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial.

Nature medicine·2026

Sporadic abdominopelvic neurofibroma presenting with genitourinary symptoms: A case report.

Urology case reports·2026

Neddylation-dependent RAB40-Cullin5 E3 ligase complex controls ubiquitin-mediated proteasomal degradation of DNAJC13.

BBA advances·2026

Dual inhibitory potential of N-methylcytisine against GSK-3β and AChE: implications for Alzheimer's disease treatment.

Open life sciences·2026

Long non-coding RNAs in glial cells: key drivers of neuroinflammation in cognitive disorders.

Frontiers in aging neuroscience·2026

The cGAS-STING Pathway Drives Astrocyte-Mediated Demyelination in Multiple Sclerosis Through Clusterin Secretion.

CNS neuroscience & therapeutics·2026

Serum Biomarkers of Neuroaxonal and Astroglial Damage in Autism Spectrum Disorder: Relationship With Symptom Severity, Behavioural Dimensions and Age.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us